Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Aprelikova Website

Olga Aprelikova, Ph.D.

Selected Publications

1)  Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A, Niederhuber J.
The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts.
Cell Cycle. 9: 4387-98, 2010.
2)  Aprelikova O, Pandolfi S, Tackett S, Ferreira M, Salnikow K, Ward Y, Risinger JI, Barrett JC, Niederhuber J.
Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.
Cancer Res. 69: 616-24, 2009.
3)  Aprelikova O.
The roads to tumor starvation.
Cell Cycle. 8: 2868, 2009.
4)  Salnikow K, Aprelikova O, Ivanov S, Tackett S, Kaczmarek M, Karaczyn A, Yee H, Kasprzak KS, Niederhuber J.
Regulation of hypoxia-inducible genes by ETS1 transcription factor.
Carcinogenesis. 29: 1493-9, 2008.
5)  Evans TA, Raina AK, Delacourte A, Aprelikova O, Lee H, Zhu X, Perry G, Smith MA.
BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease.
Int J Medical Sci. 4: 140-5, 2007.
6)  Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, Berchuck A, Lobanenkov V, Barrett JC.
Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.
Clin. Cancer Res. 13: 1713-9, 2007.
7)  Riss J, Khanna C, Koo S, Chandramouli GV, Yang HH, Hu Y, Kleiner DE, Rosenwald A, Schaefer CF, Ben-Sasson SA, Yang L, Powell J, Kane DW, Star RA, Aprelikova O, Bauer K, Vasselli JR, Maranchie JK, Kohn KW, Buetow KH, Linehan WM, Weinstein JN, Lee MP, Klausner RD, Barrett JC.
Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma.
Cancer Res. 66: 7216-24, 2006.
8)  Aprelikova O, Wood M, Tackett S, Chandramouli GV, Barrett JC.
Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection.
Cancer Res. 66: 5641-7, 2006.
9)  Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J.
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.
Clin. Cancer Res. 11: 6300-10, 2005.
10)  Risinger JI, Maxwell GL, Chandramouli GV, Aprelikova O, Litzi T, Umar A, Berchuck A, Barrett JC.
Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.
Cancer Res. 65: 5031-7, 2005.
11)  Turner JM, Aprelikova O, Xu X, Wang R, Kim S, Chandramouli GV, Barrett JC, Burgoyne PS, Deng CX.
BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation.
Curr. Biol. 14: 2135-42, 2004.
12)  Jazaeri AA, Chandramouli GV, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, Ropers HH, Yee CJ, Boyd J, Barrett JC.
BRCA1-mediated repression of select X chromosome genes.
J Transl Med. 2: 32, 2004.
13)  Kohn KW, Riss J, Aprelikova O, Weinstein JN, Pommier Y, Barrett JC.
Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system.
Mol. Biol. Cell. 15: 3042-52, 2004.
14)  Aprelikova O, Chandramouli GV, Wood M, Vasselli JR, Riss J, Maranchie JK, Linehan WM, Barrett JC.
Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors.
J. Cell. Biochem. 92: 491-501, 2004.
15)  Alleman WG, Tabios RL, Chandramouli GV, Aprelikova ON, Torres-Cabala C, Mendoza A, Rogers C, Rodgers C, Sopko NA, Linehan WM, Vasselli JR.
The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.
Clin. Cancer Res. 10: 7011-21, 2004.
16)  Novoradovskaya N, Whitfield ML, Basehore LS, Novoradovsky A, Pesich R, Usary J, Karaca M, Wong WK, Aprelikova O, Fero M, Perou CM, Botstein D, Braman J.
Universal Reference RNA as a standard for microarray experiments.
BMC Genomics. 5: 20, 2004.
17)  Xu X, Aprelikova O, Moens P, Deng CX, Furth PA.
Impaired meiotic DNA-damage repair and lack of crossing-over during spermatogenesis in BRCA1 full-length isoform deficient mice.
Development. 130: 2001-12, 2003.
18)  Risinger JI, Maxwell GL, Chandramouli GV, Jazaeri A, Aprelikova O, Patterson T, Berchuck A, Barrett JC.
Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer.
Cancer Res. 63: 6-11, 2003.
19)  Aprelikova O, Pace AJ, Fang B, Koller BH, Liu ET.
BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells.
J. Biol. Chem. 276: 25647-50, 2001.
20)  Campbell M, Aprelikova ON, van der Meer R, Woltjer RL, Yee CJ, Liu ET, Jensen RA.
Construction and characterization of recombinant adenoviruses expressing human BRCA1 or murine Brca1 genes.
Cancer Gene Ther. 8: 231-9, 2001.
21)  Aprelikova ON, Fang BS, Meissner EG, Cotter S, Campbell M, Kuthiala A, Bessho M, Jensen RA, Liu ET.
BRCA1-associated growth arrest is RB-dependent.
Proc. Natl. Acad. Sci. U.S.A. 96: 11866-71, 1999.
22)  Aprelikova O, Kuthiala A, Bessho M, Ethier S, Liu ET.
BRCA1 protein level is not affected by peptide growth factors in MCF10A cell line.
Oncogene. 13: 2487-91, 1996.
23)  Yarbrough WG, Aprelikova O, Pei H, Olshan AF, Liu ET.
Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele.
J. Natl. Cancer Inst. 88: 1489-91, 1996.
24)  Aprelikova O, Xiong Y, Liu ET.
Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase.
J. Biol. Chem. 270: 18195-7, 1995.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/26/2011.